Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests

Mary A Rodgers^{*1}, Rahul Batra², Luke B Snell², David Daghfal¹, Richard Roth³, Shihai Huang⁴, Stephen Kovacs⁵, Gaia Nebbia², Sam Douthwaite², Gavin A Cloherty¹

¹ Abbott Diagnostics, Abbott Park, IL 60064

² Guy's and St Thomas' NHS Foundation, London, UK

³ Abbott Rapid Diagnostics, San Diego, CA

⁴ Abbott Molecular Diagnostics, Des Plaines, IL

⁵ Abbott Rapid Diagnostics, Scarborough, ME

*Corresponding author: Mary A Rodgers, 100 Abbott Park Rd, Abbott Park, IL 60064

Highlights:

- Abbott SARS-CoV-2 molecular and antigen assays detect B.1.1.7, B.1.351, and P.1 variants
- Abbott SARS-CoV-2 antibody assays detect B.1.1.7 antibodies in recovered patient sera
- Quantitation of viral load in genome equivalents allows comparison of assay performance

Abstract

Background: Viral diversity presents an ongoing challenge for diagnostic tests, which need to accurately detect all circulating variants. The Abbott Global Surveillance program monitors severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and their impact on diagnostic test performance.

Objectives: To evaluate the capacity of Abbott molecular, antigen, and serologic assays to detect the SARS-CoV-2 B.1.1.7, B.1.351 and the P.1 variants.

Study design: Virus variant culture stock dilutions (B.1.1.7, BEI NR-54011; B.1.351, BEI NR-54008 and 54009; P.1, BEI NR-54982) and clinical samples from patients with confirmed B.1.1.7 variant infection were run on the Abbott ID NOW COVID-19, *m2000* RealTime SARS-CoV-2, Alinity m SARS-CoV-2, and Alinity m Resp-4-Plex molecular assays; the BinaxNOW COVID-19 Ag Card and Panbio COVID-19 Ag Rapid Test Device; and the ARCHITECT/Alinity i SARS-CoV-2 IgG and AdviseDx IgM assays, Panbio COVID-19 IgG assay, and ARCHITECT/Alinity i AdviseDx SARS-CoV-2 IgG II assay.

Results: Cultured virus stocks and B.1.1.7 clinical samples were detected with molecular, antigen, and serologic assays in the expected ranges, confirming *in silico* predictions. The ratio between genome equivalents (GE) and calculated median tissue culture infectious dose (TCID₅₀) were 31- to 83-fold higher for B.1.1.7 cultures compared to B.1.351 and P.1 cultures, demonstrating that GE are more consistent units between cultures than TCID₅₀.

Conclusions: Abbott molecular and antigen assays effectively detect B.1.1.7, B.1.351, and P.1 variant infections and Abbott serologic assays detect B.1.1.7 antibodies in patient sera. Future studies with SARS-CoV-2 virus cultures should use quantitative viral load values to compare detection of variants.

Keywords: SARS-CoV-2, diagnostics, B.1.1.7 variant, B.1.351 variant, P.1 variant

1. Background

As viruses continue to evolve, diagnostic tests must keep pace to ensure accurate detection of all circulating variants. While assay design can mitigate the impact of viral diversity, assay performance must be continually monitored through variant testing and molecular surveillance. To meet this challenge, the Abbott Global Surveillance program has been tracking the sequences of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants that have emerged throughout the pandemic, including three major lineages that have spread globally: B.1.1.7, B.1.351, and P.1. The B.1.1.7 lineage was first identified in the United Kingdom and carries spike mutations that have been linked to increased transmissibility, including N501Y [1-3]. The B.1.351 lineage was first identified in South Africa and has since spread to more than a dozen countries, with initial reports indicating that this variant can escape neutralizing antibodies [4-6]. The P.1 variant was first reported in Japan as a branch of the B.1.128 lineage, but was subsequently traced back to Brazil. The P.1 variant contains similar mutations in the spike gene as the B.1.1.7 and B.1.351 variants, suggesting a convergence of SARS-CoV-2 spike mutations that may increase transmissibility and risk of re-infection [7]. While spike gene mutations primarily define all three of the major variant lineages, the presence of additional mutations throughout the genome warrant further examination for potential impact on diagnostic assay performance.

2. Objective

The goal of this study was to evaluate the performance of Abbott SARS-CoV-2 molecular, antigen, and serological assays to detect SARS-CoV-2 B.1.17, B.1.351, and P.1 variants and B.1.1.7 antibodies.

3. Study design

B.1.1.7, B.1.351, and P.1 lineage sequences were obtained from GISAID [8] for *in silico* comparison to assay target sequences. Virus cultures for the B.1.1.7 variant (BEI NR-54011) [9], the B.1.351 variant (BEI NR-54008, NR-54009) [10, 11], and the P.1 variant (BEI NR-54982) [12] were heat inactivated at 65°C for 30 minutes and diluted for testing with the Abbott ID NOW COVID-19, *m2000 RealTime SARS-CoV-2*, Alinity m SARS-CoV-2, and Alinity m Resp-4-Plex molecular assays; and the BinaxNOW COVID-19 Ag Card and Panbio COVID-19 Ag Rapid Test Device. Antigen testing was performed by pipetting the virus stock dilution directly onto a sterile swab and then following the manufacturer's instructions for use.

Anonymized leftover patient nasopharyngeal swab samples in viral transport media (VTM), collected at the point of discard from inpatients at Guys' and St Thomas' Hospital in London (UK Research Ethics Committee 20/SC/0310), were sequenced using the ARTIC protocol [13] on Nanopore instruments to determine infection with the B.1.1.7 variant, then run neat or diluted 5-62.5x before molecular testing on the Abbott ID NOW COVID-19, *m2000 RealTime SARS-CoV-2*, Alinity m SARS-CoV-2, and Alinity m Resp-4-Plex. Matched serum samples from the same patients were used for serologic testing with the ARCHITECT/Alinity i SARS-CoV-2 IgG and AdviseDx IgM assays, Panbio COVID-19 IgG assay, and ARCHITECT/Alinity i AdviseDx SARS-CoV-2 IgG II assay. All molecular and serological assays were performed per the manufacturer's instructions for use.

4. Results

Initial *in silico* examination of B.1.1.7, B.1.351, or P.1 sequences revealed no lineage-defining mutations of concern for the performance of Abbott assays targeting the RDRP region (ID NOW COVID-19, *m2000 RealTime SARS-CoV-2*, Alinity m SARS-CoV-2, Alinity m Resp-4-Plex), nucleocapsid region (*m2000 RealTime SARS-CoV-2*, Alinity m SARS-CoV-2, Alinity m Resp-4-

Plex, BinaxNOW COVID-19 Ag Card, Panbio COVID-19 Ag Rapid Test Device, ARCHITECT/Alinity i SARS-CoV-2 IgG, and Panbio COVID-19 IgG), and spike region (ARCHITECT/Alinity i AdviseDx SARS-CoV-2 IgM, ARCHITECT/Alinity i AdviseDx SARS-CoV-2 IgG II). To evaluate these predictions for Abbott's molecular and antigen assays, dilution series of heat-inactivated B.1.1.7 (BEI NR-54011) [9], B.1.351 (BEI NR-54008, NR-54009) [10, 11], and P.1 (BEI NR-54982) [12] virus cultures were tested on each assay. Multiple dilutions were detected with *m*2000, Alinity m, ID NOW, BinaxNOW, and Panbio Ag assays in the expected ranges previously observed with other strains (Tables 1-3) [14, 15]. These results confirm the *in silico* predictions and are consistent with recent Panbio Ag evaluations of the B.1.1.7 and B.1.351 lineages [16, 17].

Considerable variability was observed in the ratio between genome equivalents (GE) quantitated with a standard curve and the calculated median tissue culture infectious dose (TCID₅₀) for each virus isolate stock (Table 4). The GE/TCID₅₀ ratios were 23 to 102-fold higher on average for the B.1.1.7 culture than either of the B.1.351 stocks or the P.1 stock. This difference should be taken into account when evaluating assay performance with SARS-CoV-2 virus cultures and highlights the need for standardized comparisons in units that are independent of virus culture conditions, which can vary between preparations.

Further evaluation was performed with leftover nasopharyngeal swab samples in VTM and matched serum samples from 20 patients with sequence confirmed B.1.1.7 infections. Nineteen VTM samples were run on the *m*2000 and both Alinity m SARS-CoV-2 assays; the sample volume from patient #19 was not sufficient for any molecular testing. The B.1.1.7 variant was detected in all 19 samples by the *m*2000 and both Alinity m assays and was detected in all 13 samples with sufficient volume by the Alinity Resp-4-Plex assay (Table 1). Three samples had sufficient volume for testing with ID NOW; the B.1.1.7 variant was detected in all three (Table 2).

Serological assays were run with serum collected from the same B.1.1.7 patients 15-26 days post symptom onset (Table 4). Notably, three immune-compromised patients (#2, #4, and #10) were included in the panel. Antibodies for patients #2 and #4 were detected by four assays (ARCHITECT and Alinity i IgM and IgG II), but not by ARCHITECT, Alinity i, or Panbio IgG assays. Patient #10 had cancer and did not have a detectable antibody response at 15 days post symptom onset by any assay. Excluding immune-compromised patients, antibodies were detected in 100% (17/17) of patients by ARCHITECT/Alinity i IgM and IgG II assays and were detected in 94% (16/17) of patients by ARCHITECT/Alinity i, and Panbio IgG assays (Table 5).

5. Discussion

Viral diversity will continue to challenge diagnostic tests as new SARS-CoV-2 strains arise and spread globally. Of particular interest are the B.1.1.7, B.1.351, and P.1 lineages that have been linked to increased transmissibility and immune escape [1-7]. *In silico* analyses did not predict impact to detection by Abbott molecular, antigen, and antibody assays; however, these predictions need to be continually tested. This study confirmed that Abbott COVID-19 molecular, antigen, and serological assays effectively detect SARS-CoV-2 B.1.1.7, B.1.351, and P.1 variant infections and B.1.1.7 antibodies.

In comparison to other RNA viruses, SARS coronaviruses maintain a higher rate of fidelity during replication due to an encoded proofreading mechanism [18]. Indeed, SARS-CoV-2 variants are typically defined by a pattern of mutations totaling <30 positions per genome (0.1% divergence), which is much lower than the divergence of 30% or more between HCV genotypes, for example [8, 19, 20]. In particular, antibody assays are less prone to impact due to the redundant nature of polyclonal immune responses as illustrated by the detection of spike antibodies in the sera of B.1.1.7 patients (Table 4). This observation is consistent with recent studies reporting that

polyclonal antibodies in convalescent plasma bind the spike protein of SARS-CoV-2 B.1.1.7 and B.1.351 variants with similar binding kinetics despite variable capacity to neutralize the virus [21, 22]. Future studies should continue to explore the potential impact of SARS-CoV-2 sequence variation on diagnostic tests.

Acknowledgements: This study was funded by Abbott Laboratories.

References

- [1] Investigation of novel SARS-COV-2 variant: Variant of Concern 202012/01. [Updated March 11, 2021]. <https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201> Accessed March 15, 2021.
- [2] Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Transmission of SARS-CoV-2 lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. MedRxiv. 2021. doi: 10.1101/2020.12.30.20249034
- [3] Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. [Updated Dec 2020]. <https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563>. Accessed March 15, 2021.
- [4] Diamond M, Chen R, Xie X, Case J, Zhang X, VanBlargan L, et al. SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies. Res Sq. 2021. doi: 10.21203/rs.3.rs-228079/v1
- [5] Tada T, Dcosta BM, Samanovic-Golden M, Herati RS, Cornelius A, Mulligan MJ, et al. Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. bioRxiv. 2021. doi: 10.1101/2021.02.05.430003

- 176 [6] Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al.
 177 Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus
 178 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. MedRxiv. 2020. doi:
 179 10.1101/2020.12.21.20248640
- 180 [7] Faria N, Claro IM, Candido D, Franco LAM, Andrade PS, Coletti TM, et al. Genomic
 181 characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings.
 182 [Updated January 12, 2021]. [https://virological.org/t/genomic-characterisation-of-an-emergent-](https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586)
 183 [sars-cov-2-lineage-in-manaus-preliminary-findings/586](https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586). Accessed April 6, 2021.
- 184 [8] Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution
 185 to global health. Glob Chall. 2017;1:33-46. doi: 10.1002/gch2.1018
- 186 [9] The following reagent was deposited by Centers for Disease Control and Prevention and
 187 obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate
 188 USA/CA_CDC_5574/2020, NR-54011.
- 189 [10] The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related
 190 Coronavirus 2, Isolate hCoV-19/South Africa/KRISP-EC-K005321/2020, NR-54008, contributed
 191 by Alex Sigal and Tulio de Oliveira.
- 192 [11] The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related
 193 Coronavirus 2, Isolate hCoV-19/South Africa/KRISP-K005325/2020, NR-54009, contributed by
 194 Alex Sigal and Tulio de Oliveira.
- 195 [12] The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related
 196 Coronavirus 2, Isolate hCoV-19/Japan/TY7-503/2021, NR-54982, contributed by M Takayama-
 197 Ito.
- 198 [13] Artic Network. SARS-CoV-2. [Updated April 14, 2021]. <https://artic.network/ncov-2019>.
 199 Accessed April 14, 2021.

200 [14] Fung B, Gopez A, Servellita V, Arevalo S, Ho C, Deucher A, et al. Direct comparison of
 201 SARS-CoV-2 analytical limits of detection across seven molecular assays. J Clin Microbiol.
 202 2020;58. doi: 10.1128/JCM.01535-20

203 [15] Pilarowski G, Lebel P, Sunshine S, Liu J, Crawford E, Marquez C, et al. Performance
 204 characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in
 205 San Francisco. J Infect Dis. 2021. doi: 10.1093/infdis/jiaa802

206 [16] SARS-CoV-2 Lateral Flow Antigen Tests Evaluation of VUI-20201201. [Updated
 207 December 23, 2020]. [https://www.gov.uk/government/publications/sars-cov-2-lateral-flow-](https://www.gov.uk/government/publications/sars-cov-2-lateral-flow-antigen-tests-evaluation-of-vui-20201201/sars-cov-2-lateral-flow-antigen-tests-evaluation-of-vui-20201201)
 208 [antigen-tests-evaluation-of-vui-20201201/sars-cov-2-lateral-flow-antigen-tests-evaluation-of-](https://www.gov.uk/government/publications/sars-cov-2-lateral-flow-antigen-tests-evaluation-of-vui-20201201/sars-cov-2-lateral-flow-antigen-tests-evaluation-of-vui-20201201)
 209 [vui-20201201](https://www.gov.uk/government/publications/sars-cov-2-lateral-flow-antigen-tests-evaluation-of-vui-20201201/sars-cov-2-lateral-flow-antigen-tests-evaluation-of-vui-20201201). Accessed March 15, 2021.

210 [17] Akingba OL, Sprong K, Hardie DR. Field performance evaluation of the PanBio rapid
 211 SARS-CoV-2 antigen assay in an epidemic driven by 501Y.v2 (lineage B.1.351) in the Eastern
 212 Cape, South Africa. MedRxiv. 2021. doi: 10.1101/2021.02.03.21251057

213 [18] Sevajol M, Subissi L, Decroly E, Canard B, Imbert I. Insights into RNA synthesis, capping,
 214 and proofreading mechanisms of SARS-coronavirus. Virus Res. 2014;194:90-9. doi:
 215 10.1016/j.virusres.2014.10.008

216 [19] Hodcroft E. [Updated April 12, 2021]. <https://covariants.org>. Accessed April 14, 2021.

217 [20] Petruzzello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global
 218 epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of
 219 hepatitis C virus genotypes. World J Gastroenterol. 2016;22:7824-40. doi:
 220 10.3748/wjg.v22.i34.7824

221 [21] Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al.
 222 Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding
 223 Domain by Structure-Guided High-Resolution Serology. Cell. 2020;183:1024-42 e21. doi:
 224 10.1016/j.cell.2020.09.037

225 [22] Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, et al. Sensitivity
226 of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med.
227 2021. doi: 10.1038/s41591-021-01318-5

228

Tables

Table 1. *m*2000 and Alinity m SARS-CoV-2 Assay Results With B.1.1.7, B.1.351, and P.1 Virus Culture Dilutions and B.1.1.7 Clinical Samples

	Sample ID ⁺	TCID ₅₀ /mL	Log GE/mL [*]	RealTime SARS-CoV-2	Alinity m SARS-CoV-2	Alinity m Resp-4-Plex
B.1.1.7 variant	BEI NR-54011 Dilution 1	28	6.25	4/4 Detected	4/4 Detected	4/4 Detected
	BEI NR-54011 Dilution 2	2.8	5.19	4/4 Detected	4/4 Detected	4/4 Detected
	BEI NR-54011 Dilution 3	0.28	4.00	4/4 Detected	4/4 Detected	4/4 Detected
	BEI NR-54011 Dilution 4	0.028	2.85	4/4 Detected	4/4 Detected	4/4 Detected
	Patient 1	NA [#]	6.19	1/1 Detected	1/1 Detected	QNS ⁺
	Patient 2	NA [#]	6.26	1/1 Detected	1/1 Detected	QNS ⁺
	Patient 3	NA [#]	5.32	1/1 Detected	1/1 Detected	QNS ⁺
	Patient 4	NA [#]	4.98	1/1 Detected	1/1 Detected	1/1 Detected
	Patient 5	NA [#]	4.80	1/1 Detected	1/1 Detected	1/1 Detected
	Patient 6	NA [#]	4.51	1/1 Detected	1/1 Detected	1/1 Detected
	Patient 7	NA [#]	3.94	1/1 Detected	1/1 Detected	1/1 Detected
	Patient 8	NA [#]	3.72	1/1 Detected	1/1 Detected	1/1 Detected
	Patient 9	NA [#]	5.50	1/1 Detected	1/1 Detected	1/1 Detected
	Patient 10	NA [#]	2.22	1/1 Detected	1/1 Detected	1/1 Detected
	Patient 11	NA [#]	2.38	1/1 Detected	1/1 Detected	QNS ⁺
	Patient 12	NA [#]	3.35	1/1 Detected	1/1 Detected	1/1 Detected
	Patient 13	NA [#]	4.11	1/1 Detected	1/1 Detected	1/1 Detected
	Patient 14	NA [#]	3.91	1/1 Detected	1/1 Detected	QNS ⁺
	Patient 15	NA [#]	3.04	1/1 Detected	1/1 Detected	1/1 Detected
	Patient 16	NA [#]	3.99	1/1 Detected	1/1 Detected	1/1 Detected
	Patient 17	NA [#]	5.49	1/1 Detected	1/1 Detected	QNS ⁺
	Patient 18	NA [#]	4.96	1/1 Detected	1/1 Detected	1/1 Detected
	Patient 20	NA [#]	4.31	1/1 Detected	1/1 Detected	1/1 Detected
B.1.351 variant	BEI NR-54008 Dilution 1	28	4.63	4/4 Detected	4/4 Detected	4/4 Detected
	BEI NR-54008 Dilution 2	2.8	3.83	4/4 Detected	4/4 Detected	4/4 Detected
	BEI NR-54008 Dilution 3	0.28	2.51	4/4 Detected	4/4 Detected	4/4 Detected

	BEI NR-54008 Dilution 4	0.028	1.27	4/4 Detected	4/4 Detected	4/4 Detected
	BEI NR-54009 Dilution 1	28	4.35	4/4 Detected	4/4 Detected	4/4 Detected
	BEI NR-54009 Dilution 2	2.8	3.27	4/4 Detected	4/4 Detected	4/4 Detected
	BEI NR-54009 Dilution 3	0.28	2.11	4/4 Detected	4/4 Detected	4/4 Detected
	BEI NR-54009 Dilution 4	0.028	0.73	4/4 Detected	4/4 Detected	4/4 Detected
P.1 variant	BEI NR-54982 Dilution 1	28	4.56	4/4 Detected	4/4 Detected	4/4 Detected
	BEI NR-54982 Dilution 2	2.8	3.45	4/4 Detected	4/4 Detected	4/4 Detected
	BEI NR-54982 Dilution 3	0.28	2.39	4/4 Detected	4/4 Detected	4/4 Detected
	BEI NR-54982 Dilution 4	0.028	1.32	4/4 Detected	4/4 Detected	4/4 Detected

233 *VTM sample quantity not sufficient (QNS) for any molecular testing for patient #19. Several
 234 indicated samples did not have sufficient quantity for testing with the Alinity m Resp-4-Plex
 235 assay.

236 * Log genome equivalents (GE)/mL were calculated from a standard curve plot of TCID₅₀ vs
 237 GE with an R² value of 0.99.

238 #NA, not applicable, TCID₅₀ not determined for clinical samples.

239 Table 2. Rapid Molecular Assay Results With ID NOW COVID-19 with B.1.1.7, B.1.351, and
240 P.1 Virus Culture Dilutions and B.1.1.7 Clinical Samples

	Sample ID	TCID ₅₀ /test	Log GE/test*	IDNOW Result
B.1.1.7 variant	BEI NR-54011 Dilution 1	5.6	5.55	3/3 Detected
	BEI NR-54011 Dilution 2	0.56	4.49	3/3 Detected
	BEI NR-54011 Dilution 3	0.056	3.30	3/4 Detected
	BEI NR-54011 Dilution 4	0.0112	2.45	0/3 Detected
	Patient 4	NA [#]	4.28	1/1 Detected
	Patient 6	NA [#]	3.82	1/1 Detected
	Patient 13	NA [#]	3.41	1/1 Detected
B.1.351 variant	BEI NR-54008 Dilution 1	5.6	3.94	3/3 Detected
	BEI NR-54008 Dilution 2	2.8	3.64	3/3 Detected
	BEI NR-54008 Dilution 3	1.4	3.36	3/3 Detected
	BEI NR-54008 Dilution 4	0.56	3.00	3/3 Detected
	BEI NR-54008 Dilution 5	0.28	2.76	1/3 Detected
	BEI NR-54009 Dilution 1	5.6	3.66	3/3 Detected
	BEI NR-54009 Dilution 2	2.8	3.35	3/3 Detected
	BEI NR-54009 Dilution 3	1.4	3.04	3/3 Detected
	BEI NR-54009 Dilution 4	0.56	2.63	2/3 Detected
	BEI NR-54009 Dilution 5	0.28	2.29	0/3 Detected
P.1 variant	BEI NR-54982 Dilution 1	5.6	3.86	3/3 Detected
	BEI NR-54982 Dilution 2	2.8	3.56	3/3 Detected
	BEI NR-54982 Dilution 3	1.4	3.25	3/3 Detected
	BEI NR-54982 Dilution 4	0.56	2.83	3/3 Detected
	BEI NR-54982 Dilution 5	0.28	2.49	3/3 Detected
	BEI NR-54982 Dilution 6	0.14	2.19	1/3 Detected

241 [#]NA, not applicable, TCID₅₀ not determined for clinical samples.

242 * Log genome equivalents (GE)/test were calculated from a standard curve plot of TCID₅₀ vs
243 GE with an R² value of 0.99.

Table 3. Rapid Antigen Assay Results with Virus Culture Dilutions for B.1.1.7 (BEI NR-54011), B.1.351 (BEI NR-54008 and 54009), and P.1 (NR-54982)

	Culture	TCID ₅₀ /test	Log GE/test*	BinaxNOW Result	Panbio Ag Result
B.1.1.7 variant	Neat	560	7.56	1/1 Positive	1/1 Positive
	BEI NR-54011 Dilution 1	56	6.56	4/4 Positive	3/3 Positive
	BEI NR-54011 Dilution 2	28	6.26	4/4 Positive	3/3 Positive
	BEI NR-54011 Dilution 3	14	5.96	3/4 Positive	3/4 Positive
B.1.351 variant	BEI NR-54008 Dilution 1	1160	6.25	3/3 Detected	3/3 Detected
	BEI NR-54008 Dilution 2	928	6.15	3/3 Detected	3/3 Detected
	BEI NR-54008 Dilution 3	560	5.93	6/6 Detected	3/3 Detected
	BEI NR-54008 Dilution 4	56	4.93	0/3 Detected	0/3 Detected
	BEI NR-54009 Dilution 1	1160	5.98	3/3 Detected	3/3 Detected
	BEI NR-54009 Dilution 2	928	5.88	3/3 Detected	3/3 Detected
	BEI NR-54009 Dilution 3	560	5.66	6/6 Detected	3/3 Detected
	BEI NR-54009 Dilution 4	56	4.66	3/3 Detected	0/3 Detected
P.1 variant	BEI NR-54982 Dilution 1	1160	6.18	3/3 Detected	3/3 Detected
	BEI NR-54982 Dilution 2	928	6.08	3/3 Detected	3/3 Detected
	BEI NR-54982 Dilution 3	560	5.86	3/3 Detected	3/3 Detected
	BEI NR-54982 Dilution 4	280	5.56	3/3 Detected	3/3 Detected
	BEI NR-54982 Dilution 5	56	4.86	0/3 Detected	0/3 Detected

* Log genome equivalents (GE)/test were calculated from a standard curve plot of TCID₅₀ vs GE with an R² value of 0.99.

252 Table 4. Comparison of GE*/TCID₅₀ Ratios

Dilution	TCID ₅₀ /mL	B.1.1.7 variant (NR-54011)		B.1.351 variant (NR-54008)		B.1.351 variant (NR-54009)		P.1 variant (NR-54982)		Fold difference in GE/TCID		
		Mean log GE/mL	GE/TCID ₅₀ ratio	Mean log GE/mL	GE/TCID ₅₀ ratio	Mean log GE/mL	GE/TCID ₅₀ ratio	Mean log GE/mL	GE/TCID ₅₀ ratio	Ratio NR-54011/ NR-54008	Ratio NR-54011/ NR-54009	Ratio NR-54011/ NR-54982
1	28	6.25	65189	4.63	1540	4.35	809	4.56	1296	42	81	50
2	2.8	5.19	55963	3.83	2454	3.27	672	3.45	1020	23	83	55
3	0.28	4.00	36169	2.51	1193	2.11	471	2.39	913	30	77	40
4	0.028	2.85	25294	1.27	674	0.73	248	1.32	755	38	102	33
Average	NA	NA	45654	NA	1465	NA	550	NA	996	31	83	46

253 * Genome equivalents (GE)/mL were calculated from a standard curve plot of TCID₅₀ vs GE with an R² value of 0.99.

254

Table 5. SARS-CoV-2 Serology Assay Results with B.1.1.7 Clinical Samples

Sample ID	ARCH IgM (Index) [†]	Alinity IgM (Index) [†]	ARCH IgG (Index) [†]	Alinity IgG (Index) [†]	ARCH IgG II (AU/mL) [†]	Alinity IgG II (AU/mL) [†]	Panbio IgG Result	Days post symptom onset
Patient 1	18.36	18.68	6.76	6.97	13359.5	11595.4	Positive	26
Patient 2	1.22	1.26	0.22	0.22	178.5	189.5	Negative	20
Patient 3	11.68	12.05	5.62	6.01	5288.1	6570.1	Positive	19
Patient 4	11.71	11.04	0.8	0.87	149.4	153.7	Negative	25
Patient 5	6.47	6.58	5.29	5.44	5472.9	5468.1	Positive	20
Patient 6	1.31	1.32	6.6	6.58	> 40000.0	> 40000.0	Positive	16
Patient 7	14.16	13.51	6.8	6.98	12034.7	11191.5	Positive	22
Patient 8	7.41	7.2	6.39	6.36	14489.9	12718.3	Positive	21
Patient 9	15.15	14.86	4.73	4.82	2745.6	2603.7	Positive	20
Patient 10	0.03	0.04	0.02	0.02	0.9	0.2	Negative	15
Patient 11	1.27	1.22	0.22	0.23	186.4	186.8	Negative	20
Patient 12	26.79	26.67	6.62	6.6	22392.8	19367.7	Positive	23
Patient 13	5.81	6.06	4.31	4.33	1255.4	1183.3	Positive	19
Patient 14	88.25	88.59	6.67	6.42	6811.4	6250	Positive	16
Patient 15	88.27	88.14	6.66	6.58	6815.2	6587.5	Positive	21
Patient 16	88.87	89.11	6.39	6.5	6924.4	6401.6	Positive	18
Patient 17	2.09	2.2	6.23	6.19	1626.4	1630.5	Positive	17
Patient 18	91.31	87.56	6.62	6.55	7459.3	6330	Positive	19
Patient 19	4.56	4.58	7.36	7.31	2345.6	2274.9	Positive	19
Patient 20	4.55	4.61	7.18	7.53	2491.1	2236.1	Positive	20

[†]An index value of ≥ 1.4 is positive for IgG assays, ≥ 1.0 is positive for IgM assays, a result of ≥ 50 AU/ml per mL is positive for IgG II assays.